Shuishen Zhang1, Minghan Jia2, Xiaoli Cai3, Weixiong Yang1, Shufen Liao4, Zhenguo Liu1, Jing Wen5,6, Kongjia Luo5,6,7, Chao Cheng1. 1. Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. 2. Department of Breast Cancer, Guangdong Provincial People's Hospital Cancer Center, Guangdong Academy of Medical Sciences, Guangzhou, China. 3. Department of Medical Ultrasonics, First Affiliated Hospital of Jinan University, Guangzhou, China. 4. Operating room of the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. 5. Guangdong Esophageal Cancer Institute, Guangzhou, China. 6. Department of Thoracic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. 7. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Abstract
BACKGROUND: The prognostic value of ABO blood types is not well clarified for esophageal carcinoma (EC). This study attempted to elucidate the associations between different ABO blood types and disease-free survival (DFS) and overall survival (OS) of EC. METHODS: This study was a retrospective review of the records of 2179 patients with EC who received surgery from December 2000 to December 2008. The prognostic impact of ABO blood group on DFS and OS were estimated using the Kaplan-Meier method and cox proportional hazard models. RESULTS: Univariate analyses found significant differences in DFS and OS among the four blood types. Multivariate analyses showed ABO blood type independently predicted DFS (P=0.001) and OS (P=0.002). Furthermore, patients with non-B blood types had a significantly shorter DFS (HR=1.22, 95%CI:1.07-1.38, P=0.002) and OS (HR=1.22, 95%CI:1.07-1.38, P=0.003) than patients with blood type B, and patients with non-O blood types had a significantly better DFS (HR=0.86, 95%CI:0.77-0.96, P=0.006) and OS (HR=0.86, 95%CI:0.77-0.96, P=0.007) than patients with blood type O. Subgroup analyses found that blood type B had a better DFS and OS than non-B in patients who were male, younger, early pathological stages and had squamous-cell carcinomas (ESCC). Blood type O had a worse DFS and OS than non-O in patients who were male, younger, and had ESCC (P<0.05). CONCLUSIONS: The results demonstrate that ABO blood group is an independent prognostic factor of survival, and that type B predicts a favorable prognosis, whereas type O predicts an unfavorable prognosis for survival in patients with EC, especially those with ESCC.
BACKGROUND: The prognostic value of ABO blood types is not well clarified for esophageal carcinoma (EC). This study attempted to elucidate the associations between different ABO blood types and disease-free survival (DFS) and overall survival (OS) of EC. METHODS: This study was a retrospective review of the records of 2179 patients with EC who received surgery from December 2000 to December 2008. The prognostic impact of ABO blood group on DFS and OS were estimated using the Kaplan-Meier method and cox proportional hazard models. RESULTS: Univariate analyses found significant differences in DFS and OS among the four blood types. Multivariate analyses showed ABO blood type independently predicted DFS (P=0.001) and OS (P=0.002). Furthermore, patients with non-B blood types had a significantly shorter DFS (HR=1.22, 95%CI:1.07-1.38, P=0.002) and OS (HR=1.22, 95%CI:1.07-1.38, P=0.003) than patients with blood type B, and patients with non-O blood types had a significantly better DFS (HR=0.86, 95%CI:0.77-0.96, P=0.006) and OS (HR=0.86, 95%CI:0.77-0.96, P=0.007) than patients with blood type O. Subgroup analyses found that blood type B had a better DFS and OS than non-B in patients who were male, younger, early pathological stages and had squamous-cell carcinomas (ESCC). Blood type O had a worse DFS and OS than non-O in patients who were male, younger, and had ESCC (P<0.05). CONCLUSIONS: The results demonstrate that ABO blood group is an independent prognostic factor of survival, and that type B predicts a favorable prognosis, whereas type O predicts an unfavorable prognosis for survival in patients with EC, especially those with ESCC.
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Guillaume Paré; Daniel I Chasman; Mark Kellogg; Robert Y L Zee; Nader Rifai; Sunita Badola; Joseph P Miletich; Paul M Ridker Journal: PLoS Genet Date: 2008-07-04 Impact factor: 5.917